NEW YORK (GenomeWeb) - Genomic Health and Epic Sciences today announced that they have signed an exclusive agreement under which Genomic Health will commercialize Epic Sciences' AR-V7 liquid biopsy test in the United States.
Genomic Health will also make an equity investment in Epic Sciences, but the companies did not disclose details of that investment or further financial terms of the agreement.